Current clinical and preclinical photosensitizers for use in photodynamic therapy.

By M. Detty, S. Gibson, S. Wagner. Journal of Medicinal Chemistry, 2004

905 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Photodynamic therapy and anti-tumour immunity (2006, background): “Many of the photosensitizers (PSs) that have been studied since PDT was first proposed are based on a porphyrin-like nucleu”
Photodynamic therapy of cancer. Basic principles and applications (2008, background): “Examples of new PSs are synthetic porphyrins, benzoporphyrins, chlorins, bacteriochlorophylls, pheophorbides, phthalocyanines, naphthalocyanines, natural hydroxyquinone chromophores such as hypericins, and porphycenes (which are structural isomers of porphyrins) [6, 8–10].”
A Review of Progress in Clinical Photodynamic Therapy (2005, background): “Clinicians and chemists have different views on what is the ideal photosensitizer (16, 17).”
Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy (2009, background): “Pc exhibits strong absorption bands at 670–770 nm in the red region of the spectrum and the presence of an appropriate central atom, such as zinc, aluminum or silicon, yields high singlet oxygen production with long-lived triplet states (134,135).”